New Risk • May 21
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 35% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risks Dividend is not well covered by cash flows (110% cash payout ratio). Large one-off items impacting financial results. Board Change • May 21
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Mar 05
Aedifica NV/SA, Annual General Meeting, May 12, 2026 Aedifica NV/SA, Annual General Meeting, May 12, 2026. Duyuru • Feb 13
Aedifica Nv/Sa Proposes Dividend The Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed. Board Change • Dec 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kari Pitkin was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Oct 14
Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026 Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026 Duyuru • Feb 27
Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025 Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025 Duyuru • Nov 22
Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025 Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: €0.61 (vs €0.69 in 3Q 2023) Third quarter 2024 results: EPS: €0.61 (down from €0.69 in 3Q 2023). Revenue: €87.8m (up 7.9% from 3Q 2023). Net income: €28.8m (down 12% from 3Q 2023). Profit margin: 33% (down from 40% in 3Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Duyuru • Oct 30
Aedifica NV/SA Increases Earnings Guidance for the Year 2024 Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share). Duyuru • Oct 23
Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025 Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025 Buy Or Sell Opportunity • Sep 17
Now 21% undervalued Over the last 90 days, the stock has risen 13% to €62.90. The fair value is estimated to be €79.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 162% in the next 2 years. Duyuru • Sep 10
Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited. Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million.
Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. Buy Or Sell Opportunity • Aug 27
Now 20% undervalued Over the last 90 days, the stock has risen 5.2% to €61.40. The fair value is estimated to be €76.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 8.1% in 2 years. Earnings are forecast to grow by 162% in the next 2 years. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: €1.40 (vs €1.02 in 2Q 2023) Second quarter 2024 results: EPS: €1.40 (up from €1.02 in 2Q 2023). Revenue: €86.4m (up 8.3% from 2Q 2023). Net income: €66.5m (up 64% from 2Q 2023). Profit margin: 77% (up from 51% in 2Q 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Duyuru • Jul 31
Aedifica NV/SA Provides Earnings Guidance for the Year 2024 Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share). Upcoming Dividend • May 09
Upcoming dividend of €1.60 per share Eligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Trailing yield: 6.2%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (7.3%). Reported Earnings • May 02
First quarter 2024 earnings released: EPS: €1.59 (vs €0.40 in 1Q 2023) First quarter 2024 results: EPS: €1.59 (up from €0.40 in 1Q 2023). Revenue: €84.2m (up 7.2% from 1Q 2023). Net income: €75.6m (up 369% from 1Q 2023). Profit margin: 90% (up from 21% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 05
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 85%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year. Declared Dividend • Feb 23
Final dividend of €1.60 announced Shareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.8%, which is higher than the industry average of 3.8%. Reported Earnings • Feb 22
Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022) Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.4m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year. Buy Or Sell Opportunity • Feb 02
Now 23% undervalued The stock has been flat over the last 90 days, currently trading at €57.70. The fair value is estimated to be €74.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has declined by 5.3%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 41% per annum over the same time period. Price Target Changed • Jan 31
Price target decreased by 11% to €66.00 Down from €74.22, the current price target is an average from 11 analysts. New target price is 11% above last closing price of €59.50. Stock is down 26% over the past year. The company is forecast to post earnings per share of €1.47 for next year compared to €8.71 last year. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €56.55, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €82.45 per share. Price Target Changed • Nov 05
Price target decreased by 7.1% to €73.88 Down from €79.50, the current price target is an average from 10 analysts. New target price is 28% above last closing price of €57.70. Stock is down 26% over the past year. The company is forecast to post earnings per share of €2.64 for next year compared to €8.71 last year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022) Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Duyuru • Aug 04
Aedifica NV/SA Revises Earnings Guidance for the Year 2023 Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share). Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: €1.02 (vs €3.35 in 2Q 2022) Second quarter 2023 results: EPS: €1.02 (down from €3.35 in 2Q 2022). Revenue: €79.8m (up 16% from 2Q 2022). Net income: €40.6m (down 67% from 2Q 2022). Profit margin: 51% (down from 177% in 2Q 2022). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Buying Opportunity • Jul 07
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be €78.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €55.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 20x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €75.91 per share. Buying Opportunity • Jun 22
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be €78.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Duyuru • Jun 02
An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million. An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023. Buying Opportunity • May 31
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be €80.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 6.6% per annum. Earnings is also forecast to grow by 34% per annum over the same time period. Price Target Changed • May 23
Price target decreased by 11% to €79.50 Down from €89.00, the current price target is an average from 8 analysts. New target price is 20% above last closing price of €66.25. Stock is down 39% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €8.71 last year. Reported Earnings • May 10
First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022) First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 05
Upcoming dividend of €1.60 per share at 4.9% yield Eligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%). Reported Earnings • Apr 10
Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021) Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 11% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 17
Full year 2022 earnings released Full year 2022 results: Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the REITs industry in Europe. Price Target Changed • Jan 22
Price target decreased to €90.33 Down from €98.33, the current price target is an average from 8 analysts. New target price is 9.6% above last closing price of €82.40. Stock is down 25% over the past year. The company is forecast to post earnings per share of €9.77 for next year compared to €8.10 last year. Board Change • Nov 16
High number of new directors There are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Third quarter 2022 earnings released: EPS: €3.48 (vs €1.61 in 3Q 2021) Third quarter 2022 results: EPS: €3.48 (up from €1.61 in 3Q 2021). Revenue: €64.4m (up 7.6% from 3Q 2021). Net income: €138.9m (up 139% from 3Q 2021). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 06
Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021) Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Price Target Changed • Jul 05
Price target decreased to €97.00 Down from €107, the current price target is an average from 8 analysts. New target price is 8.5% above last closing price of €89.40. Stock is down 23% over the past year. The company is forecast to post earnings per share of €10.84 for next year compared to €8.10 last year. Board Change • Jun 02
High number of new directors There are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • May 18
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 06
Upcoming dividend of €1.58 per share Eligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (4.3%). Price Target Changed • Apr 27
Price target increased to €107 Up from €93.00, the current price target is an average from 8 analysts. New target price is 6.5% below last closing price of €114. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of €11.04 for next year compared to €8.10 last year. Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020) Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 10% per year. Price Target Changed • Mar 23
Price target increased to €107 Up from €93.00, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of €109. Stock is up 12% over the past year. The company is forecast to post earnings per share of €6.88 for next year compared to €8.10 last year. Buying Opportunity • Mar 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 6.0%. The fair value is estimated to be €133, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €236.4m (up 32% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 18% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 6% per year. Price Target Changed • Feb 05
Price target decreased to €86.00 Down from €93.00, the current price target is an average from 7 analysts. New target price is 17% below last closing price of €103. Stock is down 0.2% over the past year. The company is forecast to post earnings per share of €8.09 for next year compared to €4.35 last year. Buying Opportunity • Jan 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 8.3%. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% per annum over the last 3 years. Earnings per share has grown by 6.6% per annum over the last 3 years. Reported Earnings • Nov 13
Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Oct 04
Price target increased to €93.00 Up from €81.00, the current price target is an average from 7 analysts. New target price is 15% below last closing price of €109. Stock is up 5.5% over the past year. Reported Earnings • Aug 12
Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020) Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 13
First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year. Upcoming Dividend • May 07
Upcoming dividend of €0.48 per share Eligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (3.5%). Duyuru • May 01
Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million. Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million on April 29, 2021. Aedifica SA invested €16 million in Hamberley Hailsham care home in Hailsham, East Sussex, €7 million in Villa Nuova care residence in Vorden, Bronckhorst, €1 million in Oulunsalon Vihannestie in Oulu, €3 million in Porin Kerhotie care home in Pori, €14 million in Seniorenquartier Heiligenhafen in Heiligenhafen and €16 million in Seniorenquartier Kaemenas Hof in Bremen.
Aedifica SA (ENXTBR:AED) completed the acquisition of 6 development projects in Netherlands, United Kingdom, Finland and Germany on April 29, 2021. Is New 90 Day High Low • Feb 18
New 90-day high: €104 The company is up 5.0% from its price of €98.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share. Is New 90 Day High Low • Jan 27
New 90-day high: €101 The company is up 19% from its price of €84.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €103 per share. Duyuru • Jan 16
Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million. Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million on January 14, 2021.
Aedifica SA (ENXTBR:AED) completed the acquisition of 3 nursing homes in the United Kingdom on January 14, 2021. Duyuru • Dec 18
Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million. Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million on December 17, 2020. For consideration 90,330 new shares were issued.
Aedifica SA (ENXTBR:AED) completed the acquisition of Care Home in Tienen on December 17, 2020. Is New 90 Day High Low • Oct 16
New 90-day low: €90.60 The company is down 5.0% from its price of €95.10 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.50 per share. Duyuru • Oct 02
Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million. Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million on October 1, 2020.
Aedifica SA (ENXTBR:AED) completed the acquisition of Familiehof from Vivalto Home Belgium SA on October 1, 2020. Duyuru • Sep 26
Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million. Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million on August 14, 2020.
Aedifica SA (ENXTBR:AED) completed the acquisition of Bedfordshire Care Home from Hamberley Development Limited on August 14, 2020. 
